How have the shares performed?
Enzo Biochem Inc. (ENZ) saw downtrend of -2.22% in the recent trading with $3.08 being its most recent. The current price level -36.49% lower than the highest price of $4.85 marked by the stock while trading over the past 52-weeks, whereas it is 71.11% higher than the lowest price of $1.80 the company dropped to over past 52-weeks. The latest news story on ENZ appeared in Simply Wall St. under the title “Did Enzo Biochem, Inc. (NYSE:ENZ) Insiders Buy Up More Shares?” on May-15-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -6.67% below one month high and is +12.00% above of the lowest during that time. Looking into the simple moving average, Enzo Biochem Inc. (ENZ)’s stock stands at a SMA-50 of $3.23 while that of 5-day is reading $3.08.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ENZ’s SMA-200 as of now is $2.68.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
Enzo Biochem Inc. Earnings – What Happened With ENZ
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $31.47 billion.
ENZ – Enzo Biochem Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 48.01 million. ENZ does have institutional investors; and they hold 58.00% of the stock.
Enzo Biochem Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, ENZ declared 144,768 shares have been sold in 2 insider transactions over the past three months.
As on Dec 30, 2020, Harbert Fund Advisors, Inc. was the top most holder in Enzo Biochem Inc. (NYSE:ENZ) with an ownership of 5.62 million shares of the company or 11.65% of the stake worth $14.16 million. The filing also reveals Blackrock Inc. as the second largest holder in the company with a control over 7.79% of the outstanding shares. Its stake is worth $9.46 million for having 3.76 million shares in hand.
Renaissance Technologies, LLC also came holding a key position in the company during the recent quarter and it now holds 7.37% of the outstanding shares. With this there are now 117 institutions which have possession in ENZ’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Enzo Biochem Inc. was 2.10 while posting a debt to equity ratio of 0.19. The count was 36.58 for long-term debt to equity ratio.
Enzo Biochem Inc.’s return on equity, or ROE, is -17.50%, compared to the industry average of -1.71% for Healthcare – Diagnostics & Research. Although this indicates that ENZ fails to use its equity well, the metric will vary significantly depending on the industry.